MMI — Competitive Intelligence Brief

MMI (MMI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: MAO-B inhibitor. Area: Neurology.

marketed MAO-B inhibitor MAO-B Neurology Small molecule

Target snapshot

MMI (MMI) — Xiao-Ming Mao. MMI is a selective monoamine oxidase B (MAO-B) inhibitor.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MMI TARGET	MMI	Xiao-Ming Mao	marketed	MAO-B inhibitor	MAO-B
rasagiline (Pharmacodynamics)	rasagiline (Pharmacodynamics)	University of Maryland, Baltimore	marketed	Monoamine oxidase B (MAO-B) inhibitor	MAO-B (Monoamine oxidase type B)
Rasagiline mesylate with Levodopa	Rasagiline mesylate with Levodopa	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor combined with dopamine precursor	Monoamine oxidase B (MAO-B); Dopamine pathway
Safinamide Methanesulfonate	Safinamide Methanesulfonate	Zambon SpA	marketed	Monoamine oxidase B (MAO-B) inhibitor	MAO-B (Monoamine oxidase B)
Rasagiline mesylate with Requip	Rasagiline mesylate with Requip	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor combined with dopamine receptor agonist	MAO-B and dopamine D2/D3 receptors
Safinamide (as add-on therapy)	Safinamide (as add-on therapy)	Newron Pharmaceuticals SPA	phase 3	MAO-B inhibitor	MAO-B
Rasagiline mesylate plus Mirapex	Rasagiline mesylate plus Mirapex	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor plus dopamine agonist combination	Monoamine oxidase B and dopamine D2/D3 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (MAO-B inhibitor class)

1. Newron Pharmaceuticals SPA · 1 drug in this class
2. Xiao-Ming Mao · 1 drug in this class